- Title
- Betamethasone: a neuroactive steroid deficit and adverse effects in the brain?
- Creator
- McKendry, Amy
- Relation
- University of Newcastle Research Higher Degree Thesis
- Resource Type
- thesis
- Date
- 2010
- Description
- Masters Research - Master of Philosophy (MPhil)
- Description
- There are ongoing concerns that antenatal corticosteroids, which are administered to women at high risk of delivering preterm to reduce the incidence of respiratory distress syndrome, have adverse effects on fetal brain development and subsequent effects on behaviour and learning, when administered as repeated courses. There is evidence that neuroactive steroids have a role in brain development and could be altered by antenatal corticosteroids. 5α-reductase is the key rate limiting enzyme in the synthetic pathway of the potent neuroactive steroid, allopregnanolone. The objective of this study was to examine if repeated betamethasone treatment alters 5α-reductase expression, alters plasma and brain allopregnanolone concentrations, affects brain development and whether this effect is potentiated in growth restricted fetuses. To investigate this, pregnant guinea pigs carrying either control (sham surgery) or growth-restricted fetuses were treated with vehicle or betamethasone (1mg/kg/day) for 4 days prior to sacrifice (65GA). Placental insufficiency was induced by the ablation of uterine artery branches supplying each placenta at mid gestation, resulting in fetal growth restriction characterised by ‘brain sparing’. Real time RT-PCR was used to determine relative 5α-reductase type 1 and 2 mRNA expression in the placenta, adrenal glands and brain. Radioimmunoassay was used to measure allopregnanolone concentrations in the plasma and brain. Immunohistochemistry was used to examine GFAP (marker of astrocytes) and MBP (marker of myelination) expression in the subcortical white matter, CA1 and dentate (GFAP only) regions of the hippocampus. 5α-reductase type 2 mRNA expression in the brain was markedly reduced by betamethasone treatment in male fetuses compared with vehicle treated controls but not in female fetuses. In addition, 5α-reductase type 1 expression in the brain was increased by growth restriction and/or betamethasone treatment in female fetuses but expression in male fetuses did not increase. 5α-reductase type 2 expression in the placenta was markedly reduced by betamethasone treatment compared with vehicle treated control. Plasma allopregnanolone concentration was reduced by betamethasone and IUGR. Brain allopregnanolone concentration was not significantly altered but trended towards a reduction in males with IUGR and betamethasone and an increase in females with IUGR/betamethasone. IUGR and betamethasone treatment reduced GFAP expression in the CA1 region of the hippocampus in the brains of male but not female fetuses. There were no significant changes in MBP expression in male or female fetuses. These data indicate that betamethasone treatment suppresses placental enzyme expression, plasma allopregnanolone and has sexually dimorphic effects on expression of neuroactive steroid synthetic enzymes and allopregnanolone in the brain. These actions may lead to adverse effects on the developing brain, particularly in male fetuses, such as the observed effects on GFAP expression.
- Subject
- betamethasone; neurosteroid; fetal; 5α-reductase; guinea pig
- Identifier
- http://hdl.handle.net/1959.13/805667
- Identifier
- uon:6907
- Rights
- Copyright 2010 Amy McKendry
- Language
- eng
- Full Text
- Hits: 2399
- Visitors: 2752
- Downloads: 529
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT01 | Abstract | 162 KB | Adobe Acrobat PDF | View Details Download | ||
| View Details Download | ATTACHMENT02 | Thesis | 10 MB | Adobe Acrobat PDF | View Details Download |